Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ease of Use and Safety of HOE901-U300 Pen Injector in T2DM
NCT02227212Phase 3Completed
- Sponsor
- Sanofi
- Start
- Aug 2014
- Primary completion
- Nov 2014
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of insulin glargine in type 2 diabetes mellitus (T2DM), sponsored by Sanofi. Primary endpoint: Ease-of-use / ease of learning questionnaire at 4 weeks. Started Aug 2014; status: completed.
02
Drugs
insulin glargine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02227212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02227212.